-

Natera to Report its Third Quarter Results on November 5, 2026

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2026, after the market closes on November 5, 2026. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET.

Earnings Conference Call Information

 

Event:

Natera’s Third Quarter 2026 Financial Results

Date:

November 5, 2026

Time:

4:30 p.m. ET

Live Dial-In:

1-833-461-5787 (Domestic)

 

1-585-542-9983 (International)

Conference ID:

221 556 643

Webcast:

https://events.q4inc.com/attendee/221556643

It is recommended that participants pre-register for the call. Pre-registration is available here.

A webcast replay will be available at investor.natera.com.

About Natera

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Natera, Inc.

NASDAQ:NTRA

Release Versions

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

More News From Natera, Inc.

Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Oncology (ESMO) Congress 2026. Following the presentation of several late-breaking datasets over the weekend, Natera’s technology was included in 25 abstracts, including 9 oral presentations, along with two concurrent publications. Results from the phase III VOLGA trial in muscle-invasive bladder canc...

Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing support for Renasight, Natera’s genetic test for CKD. Among the key findings were data from a large, real-worl...

ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23–26 in Madrid, Spain.New evidence highlights the power of Natera’s latest ultrasensitive molecular residual disease (MRD) technology, Signatera Genome with Phased and Structural Variants, which has demonstrat...
Back to Newsroom